Top

Published in:

01-08-2011 | Letter

Linking epidermal growth factor plasma levels with the prognosis and treatment response of colorectal cancer patients treated with a minimally invasive approach: does it have clinical utility?

Authors: John Spiliotis, Odysseas Zoras

Published in: Surgical Endoscopy | Issue 8/2011

Excerpt

Epidermal growth factor (EGF) and its receptor (EGFR) consist of four family members: EGFR or human epidermal growth factor receptor 1 (HER1), HER2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) (ERBB2), HER3 (ERBB3), and HER4 (ERBB4). The EGFR-signaling pathways regulating cell proliferation, survival, and apoptosis (cell death) have a crucial role in cancer initiation, growth, and metastasis. Mutations in EGFR and amplification of HER2 genes cause cancer and therefore have been studied extensively. …

Baselga J, Swain SM (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9:463–475PubMedCrossRef

Roukos DH (2010) Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J (in press). doi:10.1038/tpj.2010.81

Roukos DH (2011) Cancer genome explosion and systems biology: impact on surgical oncology? Ann Surg Oncol 18(1):12–15PubMedCrossRef

Roukos DH (2010) Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 11:1039–1043PubMedCrossRef

Katsios C, Ziogas DE, Roukos DH (2010) Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations, and beyond. Expert Rev Gastroenterol Hepatol 4:525–529PubMedCrossRef

Roukos DH (2010) Next-generation genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark Med 4:583–586PubMedCrossRef

Roukos DH, Katsios C, Liakakos T (2010) Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn 10:541–545PubMedCrossRef

Luchtefeld M, Whelan RL (2010) Minimally invasive colorectal resection is associated with a rapid and sustained decrease in plasma levels of epidermal growth factor (EGF) in the colon cancer setting. Surg Endosc 24:2617–2622PubMedCrossRef

Roukos DH (2009) Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg 250:650–651PubMedCrossRef

10.

Liakakos T, Roukos DH (2008) Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer? Surg Endosc 22:1402–1404PubMedCrossRef

11.

Katsios GC, Baltogiannis G, Roukos DH (2010) Laparoscopic surgery for gastric cancer: comparative-effectiveness research and future trends. Expert Rev Anticancer Ther 10:473–476PubMedCrossRef

12.

Liakakos T, Roukos D (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 22:1553–1555PubMedCrossRef

13.

Liakakos T, Roukos DH (2009) Randomized evidence for laparoscopic gastrectomy short-term quality-of-life improvement and challenges for improving long-term outcomes. Ann Surg 250:349–350PubMedCrossRef

14.

Ziogas D, Polychronidis A, Kanellos I, Roukos D (2009) Laparoscopic colectomy survival benefit for colon cancer: is evidence from a randomized trial true? Ann Surg 249:695–696PubMedCrossRef

15.

Ziogas D, Roukos D (2008) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc 22:1405–1406PubMedCrossRef

16.

Roukos DH (2010) Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol 17:14–17PubMedCrossRef

17.

Roukos DH (2010) Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn 10:33–48PubMedCrossRef

18.

Roukos DH (2010) Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11:283–287PubMedCrossRef

19.

Katsios C, Roukos DH (2010) Individual genomes and personalized medicine: life diversity and complexity. Per Med 7:347–350CrossRef

20.

Roukos DH (2010) Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 10(3):247–250PubMedCrossRef

21.

Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10(2):123–128PubMedCrossRef

22.

Roukos DH (2009) Isolated tumor cells in breast cancer. N Engl J Med 361:1994–1995; author reply 1995–1996PubMedCrossRef

23.

Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 9(10):1413–1416PubMedCrossRef

24.

Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249(6):1067–1068PubMedCrossRef

25.

Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16(10):2678–2681PubMedCrossRef

26.

Roukos DH (2010) Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev Med Devices 7(6):723–726PubMedCrossRef

Title: Linking epidermal growth factor plasma levels with the prognosis and treatment response of colorectal cancer patients treated with a minimally invasive approach: does it have clinical utility?
Authors: John Spiliotis
Odysseas Zoras
Publication date: 01-08-2011
Publisher: Springer-Verlag
Published in: Surgical Endoscopy / Issue 8/2011
Print ISSN: 0930-2794
Electronic ISSN: 1432-2218
DOI: https://doi.org/10.1007/s00464-011-1622-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Linking epidermal growth factor plasma levels with the prognosis and treatment response of colorectal cancer patients treated with a minimally invasive approach: does it have clinical utility?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2011

Experimental model of laparoscopic gastric ischemic preconditioning prior to transhiatal esophagectomy

Disk suspension method: a novel and safe technique for the retraction of the liver during laparoscopic surgery (with video)

Reply to Letter to the Editor: Re: Preoperative versus intraoperative endoscopic sphincterotomy for management of common bile duct stones. Surg Endosc (Online first)

Endoscopic access to and exploration of the lesser sac in a human cadaver model: opportunity for transgastric endoscopic pancreatic surgery (with video)

Early effects of gastric bypass on endothelial function, inflammation, and cardiovascular risk in obese patients

Barrier methods used to prevent pelvic adhesions in videolaparoscopy: experimental study in female rabbits